Sonnet BioTherapeutics Holdings, Inc. - SONN Net earnings per share for the last four quarters

Official company branding of Sonnet BioTherapeutics Holdings Inc. (SONN)

The EPS (TTM) price chart for Sonnet BioTherapeutics (SONN) shows a figure of 66.40. Quotes currently price in the lack of profitability and micro-cap status while Phase II tests are awaited. Development relies on laboratory partnerships to identify effective cytokine combinations. The technological foundation in the US enables the creation of safe oncology treatments with high efficacy.

Sonnet BioTherapeutics Holdings (SONN) Earnings per share for the last twelve months: for the period 02/11/2024 - 12/13/2025

SONN (Sonnet BioTherapeutics Holdings, Inc.): analytical breakdowns and indicator data

Initial company analysis:SONN, Sonnet BioTherapeutics
Mass-produced product of Sonnet BioTherapeutics Holdings

For the Sonnet BioTherapeutics (SONN) biotech ecosystem, characterized by a slow influx of R&D capital and stringent FDA oversight, real profit dynamics are critical. This indicator captures the daily change in trailing twelve-month (TTM) net income per share, separating fundamental results from market speculation. Analyzing the rolling annual EPS growth chart allows for the timely identification of asset overvaluation and prevents capital from being frozen at the peak of expectations.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months